AUSTIN, Texas--(BUSINESS WIRE)--ArthroCare® Corp. (Nasdaq:ARTC), a leader in developing state-of-the-art, minimally invasive surgical products, announced today that it received certain patent licenses from MarcTec, settling a patent infringement lawsuit, and that ArthroCare’s effective fourth quarter tax rate would be reduced. The company also confirmed that it expects fourth quarter earnings of approximately $0.33 per share and full year earnings of approximately $1.17 per share, prior to the cumulative impact of the settlement costs and tax benefit. Fourth quarter revenues are expected to be approximately $69.7 million, at the current First Call consensus. “Revenues increased in all divisions on both a sequential quarter and year-over-year basis,” noted Mike Baker, ArthroCare’s CEO.
